Axogen Q3 2026: Earnings Beat Expectations and Guidance Raised to $290M
As seen on the 24/7 Wall St. homepage on October 28, 2026.
Axogen raised full-year revenue guidance to at least $290 million after nerve repair demand drove a double beat. Management is targeting a prostate market entry in 2027.
Continue ReadingShow less
Axogen delivered adjusted earnings per share of $0.21 for Q3 2026, beating expectations, with revenue up 26.2% year over year and also ahead of estimates.
The sharpest growth signal came from the Breast segment, which expanded more than 50% year over year. Account productivity and high-potential accounts drove most of the gain, pointing to a more efficient commercial engine.
Management raised full-year 2026 revenue guidance to at least $290 million, representing growth of at least 29%. That figure includes a contribution from the BioCircuit Technologies acquisition, which closed October 1, 2026, and added the NerveTape coaptation aid to the product portfolio.
Sponsored
The quarter also marked a capital structure shift: a public offering left cash and equivalents at $328.9 million at quarter end. That liquidity funds the company's next strategic move.
That move is a planned entry into the prostate market beginning in 2027, an estimated total addressable market of $754 million. Axogen has already completed more than 220 procedures, with detailed outcomes set to be reported on November 9, 2026.
Mentioned: AXGN